Experimental Protection of Mice against Lethal<i>Staphylococcus aureus</i>Infection by Novel Bacteriophage φMR11

Matsuzaki, Shigenobu; Yasuda, Masahiro; Nishikawa, Hiroshi; Kuroda, Masayuki; Ujihara, Takako; Shuin, Taro; Shen, Yuan; Jin, Zhe Zhu; Fujimoto, Shigeyoshi; Nasimuzzaman, Md; Wakiguchi, Hiroshi; Sugihara, Shigeyoshi; Sugiura, Tetsuro; Koda, Shigeki; Muraoka, Asako; Imai, Shosuke

doi:10.1086/374001

Cited by 234 publications

(184 citation statements)

References 43 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…Reports have revealed that a single treatment with phage leads to recovery in mice with infections caused by E. coli (34), P. aeruginosa (12), methicillin-resistant Staphylococcus aureus (24), and vancomycin-resistant Enterococcus faecium (6). In the present study, we also found that a single treatment with phage strain KPP10 prevented the death of mice after gutderived sepsis and intraperitoneal infection with P. aeruginosa.…”

supporting

confidence: 78%

“…Phage strain KPP10 was purified essentially by the procedure used for T4-type phages (24). P. aeruginosa strain D4 was used as the host, and the bacterial strain was suspended at 1 ϫ 10 8 cells/ml in 50 ml LB broth.…”

Section: Methodsmentioning

confidence: 99%

“…The therapeutic efficacy of phage therapy against infectious diseases caused by P. aeruginosa (12), Staphylococcus aureus (including methicillin-resistant S. aureus) (24), Escherichia coli (3), Enterococcus faecium (including vancomycin-resistant Enterococcus) (6), and Streptococcus pneumoniae (16) has been shown in experimental animal models. However, the models used in those studies were simple models of infection that did not closely resemble the pathophysiologies of diseases in humans.…”

Section: Fatality Rates Among Patients With Infections Caused Bymentioning

confidence: 99%

“…However, Smith and colleagues previously showed that infections produced by phageresistant mutants of an enteropathogenic strain of E. coli and their parents could be successfully controlled with mutant phage derived from phage that had been active against the parent bacteria (33,35). Even if the bacteria acquire phage resistance, new mutant phage that acts lytically against these bacteria can be isolated (24). It is already possible to prepare a mixture of different strains of phages that would prevent the emergence of a resistant strain during phage treatment.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Watanabe

Matsumoto

Sano

et al. 2007

Antimicrob Agents Chemother

Self Cite

188

130

View full text Add to dashboard Cite

We evaluated the efficacy of bacteriophage (phage) therapy by using a murine model of gut-derived sepsis caused by Pseudomonas aeruginosa that closely resembles the clinical pathophysiology of septicemia in humans. Oral administration of a newly isolated lytic phage strain (KPP10) significantly protected mice against mortality (survival rates, 66.7% for the phage-treated group versus 0% for the saline-treated control group; P < 0.01). Mice treated with phage also had lower numbers of viable P. aeruginosa cells in their blood, liver, and spleen. The levels of inflammatory cytokines (tumor necrosis factor alpha TNF-␣, interleukin-1␤ [IL-1␤], and IL-6) in blood and liver were significantly lower in phage-treated mice than in phage-untreated mice. The number of viable P. aeruginosa cells in fecal matter in the gastrointestinal tract was significantly lower in phage-treated mice than in the saline-treated control mice. We also studied the efficacy of phage treatment for intraperitoneal infection caused by P. aeruginosa and found that phage treatment significantly improved the survival of mice, but only under limited experimental conditions. In conclusion, our findings suggest that oral administration of phage may be effective against gut-derived sepsis caused by P. aeruginosa.

show abstract

supporting

confidence: 78%

Section: Methodsmentioning

confidence: 99%

Section: Fatality Rates Among Patients With Infections Caused Bymentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Watanabe

Matsumoto

Sano

et al. 2007

Antimicrob Agents Chemother

Self Cite

188

130

View full text Add to dashboard Cite

show abstract

“…Findings shows that appropriate administration can be used to treat lethal infectious diseases caused by Escherichia coli, Vibro cholerae, Staphylococcus aureus and Salmonella spp. [7]. Phages can be delivered topically, orally, directly into body tissues, or systemically.…”

Section: Phage Therapymentioning

confidence: 99%

Phage Therapy: A Potential Alternative in the Treatment of Multi-Drug Resistant Bacterial Infections

Rao

et al. 2017

JMEN

View full text Add to dashboard Cite

The development of antibiotic-resistant in bacteria has enhanced the scope of developing alternative approaches to conventional drugs. Bacteriophage therapy is one such approach that can be used as an alternative to antibiotics. The significance of live phages in counteracting lethal infectious and life threatening diseases caused by Gram positive and Gram negative bacteria has been reported. Bacteriophage therapy is a significant alternative to antibiotics in the current era of multidrug resistant bacterial infections as phages are used topically, orally or systemically in studies reviewed. The success rates found in these studies were 80-95% with few gastrointestinal or allergic side effects. British studies also verified significant effectiveness of phages against Escherichia coli, Acinetobacter spp., Pseudomonas spp and Staphylococcus aureus. US studies dealt with improving the bioavailability of phage. Problems faced in these studies have also been discussed. Conclusively, phage therapy may prove as an important alternative to antibiotics for combating multidrug resistant pathogens. The development of severe infectious diseases resistant to antibiotics has been an issue of serious concern and this in turn has led to the discovery of alternative approaches that could replace these conventional antibiotics. Steady decline in the discovery of new class of antibiotics, has enhanced the scope of bacteriophage as an alternative to conventional antimicrobial drugs. Therefore, bacteriophage can be employed as therapeutic agent to combat infections caused by multi-drug resistance bacteria [14,15]. Keywords Clinical Studies of Phages in Human PatientsIn human, a number of infectious diseases such as septicemia, wound infections, skin infection, osteomyelitis, urinary tract infections and middle ear infections were effectively treated with phage therapy [16]. In the US, phages were commonly used for preparation of human and animal vaccine. In phage therapy, phages were used in the form of liquid suspension, tablets, creams rinses, aerosols [17,18]. Phages therapy trials have been carried out in some countries and it is discussed below. Slopek et al. [19] reported cases of the treatment of staphylococcal infected patients of which 151 cases were of mixed infection including Staphylococcus. Positive results were obtained in 75% of infected ulcerated varicose vein cases and 100% in gastrointestinal infection, pericarditis and furunculosis due to Staphylococcus. Response rates were lower for patients more than 60 years of age and in patients with mixed infections. Interestingly, parallel administration of antibiotics diminished the effectiveness of phage therapy from 95.2% to 84.9%. Polish StudiesWeber et al. [20] evaluated the extent to which orally administered anti staphylococcal and anti-pseudomonal phage were penetrated into the serum or urine of 56 patients with suppurative bacterial infection. By the tenth day of treatment, it was established that 84% serum samples and 35% urine samples contained phage ind...

show abstract

Bacteriophage: Potential Role in Food Safety

Huff¹,

Huff²,

Rath³

et al. 2004

Preharvest and Postharvest Food Safety

View full text Add to dashboard Cite

Experimental Protection of Mice against LethalStaphylococcus aureusInfection by Novel Bacteriophage φMR11

Cited by 234 publications

References 43 publications

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice

Phage Therapy: A Potential Alternative in the Treatment of Multi-Drug Resistant Bacterial Infections

Bacteriophage: Potential Role in Food Safety

Contact Info

Product

Resources

About